Novo Nordisk Backs Down: Why the Pharmaceutical Giant Dropped Its Lawsuit Against Hims & Hers

It began with a $49 tablet. It concluded with a handshake less than a month later.

Hims & Hers Health’s stock surged by over 40% on the morning of March 9, 2026, following the company’s announcement that it had reached an agreement with Novo Nordisk, the pharmaceutical behemoth that had been threatening it with a patent infringement lawsuit only weeks prior. After exchanging accusations in court documents and press releases, the two businesses were now partners. Mike Doustdar, CEO of Novo Nordisk, sounded almost happy when he appeared on CNBC. He responded, “I don’t foresee that happening,” when asked if the lawsuit might resurface. For a business dispute that had felt genuinely bitter at its most intense, it was an amazing turn.

You have to go back to early February, when Hims announced it would sell a compounded oral version of semaglutide, the active ingredient in Wegovy and Ozempic, for $49 per month, in order to understand how things got to this point. The timing was practically theatrical. Only in January did Novo Nordisk introduce its own oral Wegovy pill, which costs $149 a month. The company is primarily relying on the new formulation to stop the decline in injectable sales in the US market. Within weeks of that launch, Hims was undercutting it by $100, marketing the less expensive version directly to customers who had made GLP-1 weight-loss medications one of the most talked-about medical products in recent memory. The product was referred to by Novo Nordisk as “an unapproved, inauthentic, and untested knockoff.” That language didn’t sound like boilerplate; there was genuine anger in it.

Even by the condensed standards of the pharmaceutical industry, what transpired next happened remarkably quickly. Hims withdrew its $49 pill two days after it was announced. The withdrawal occurred just one day after FDA Commissioner Marty Makary made combative remarks in public, the FDA threatened compounding pharmacies with consequences that were anything but ambiguous, including limited access to raw ingredients and the potential for a Department of Justice referral. Hims used diplomatic language to describe the decision as the outcome of “constructive conversations with stakeholders,” which typically indicates that the discussion wasn’t totally constructive. Novo filed its lawsuit at the same time. The stock of the company increased. After-hours trading saw a nearly 14% decline in Hims shares.

Hims seemed to have been treading carefully for a longer period of time than most people were aware. The entire GLP-1 business of the company was based on a legal exception that was becoming increasingly dubious every month. Compounders were allowed to produce and market their own versions of semaglutide once it was officially placed on the FDA’s drug shortage list. That exception made some sense because a compounded substitute met a legitimate medical need if patients were unable to obtain the branded medication. However, the door should have been closed when the FDA took semaglutide off the shortage list in early 2025. Despite this, Hims continued to play the game, claiming that because its versions were “personalized” formulations, they were still permissible under a different regulation. That argument was successful until the FDA made it apparent that it would no longer be allowed to continue.

The lawsuit was always a combination of a negotiating stance and a demonstration of power for Novo Nordisk. The company had previously attempted a variation of this dance; in April 2025, it partnered with Hims to offer Wegovy at a discount via the telehealth platform. However, the partnership was terminated two months later after the company accused Hims of “deceptive” marketing that it claimed put patients at risk. In November, another attempt at a truce was made. After oral Wegovy was introduced, Hims undercut it almost instantly, and the situation collapsed once more. The pattern points to a partnership where both businesses relied on one another in some capacity but frequently stumbled over the terms.

The extent of the concessions is what distinguishes the March agreement, at least on paper. Hims committed to selling Novo’s branded injectable and oral semaglutide at the same prices as other telehealth platforms, refraining from advertising compounded GLP-1 products, and switching its current compounding clients to FDA-approved options whenever a doctor suggests it. In return, Novo withdrew the lawsuit, but discreetly kept the option to reopen it. It’s not a ceremonial reservation. In the event that Hims decides to push the limits once more, it serves as a leash and a reminder of who is in control of this arrangement.

It’s difficult to ignore the possibility that the FDA’s involvement resolved this conflict more effectively than any actual negotiations between the two companies. Regardless of Novo’s legal actions, the $49 pill strategy had an expiration date because the compounding loophole that made Hims so disruptive in the GLP-1 market was essentially being closed from above. Both parties found it easier to accept the logic of a partnership once that became clear. Hims has a legal route to the branded medications that its clients now desire. One of the nation’s fastest-growing telehealth platforms and a rival that has now decided to cease actively undermining Novo’s pricing structure provide distribution.

The question of whether this holds is quite different. The GLP-1 market is rapidly growing, the competitive landscape will continue to change, and Eli Lilly’s oral weight-loss medication orforglipron is anticipated to arrive pending FDA approval. For the time being, however, the $49 pill is no longer available, the lawsuit is on hold, and two businesses that publicly questioned each other’s integrity for months are now formally working together. The distinction between a partner and an adversary has always been more hazy in the pharmaceutical industry, as it is in most other industries.